UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 301

Sortiert nach

1083 A completed phase I/II trial of neoadjuvant chemotherapy (CT) with cisplatin and vinorelbine followed by accelerated thoracic irradiation, (TRT) in inoperable NSCLC

European journal of cancer (1990), 1995-11, Vol.31, p.S226-S226

1995

Link zum Volltext

Verfügbarkeit prüfen

19P Her2 Extracellular Domain Levels in Patients With Her2-Positive Early Breast Cancer Experiencing Disease Progression: Case-Control Comparison of Samples from the Hera Study

Annals of oncology, 2012-05, Vol.23, p.ii20

2012

Link zum Volltext

Verfügbarkeit prüfen

2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug

Annals of internal medicine, 1988-05, Vol.108 (5), p.733

1988

Link zum Volltext

Verfügbarkeit prüfen

2'-Fluoro-5-iodoarabinosylcytosine, a new potent antiviral agent: efficacy in immunosuppressed individuals with herpes zoster

The Journal of infectious diseases, 1986-09, Vol.154 (3), p.430

1986

Link zum Volltext

Verfügbarkeit prüfen

2105 POSTER An accelerated loading regimen for trastuzumab leads to early higher than steady-state serum concentrations

European journal of cancer supplements, 2007, Vol.5 (4), p.215-215

2007

Link zum Volltext

Verfügbarkeit prüfen

218PAutoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Link zum Volltext

Verfügbarkeit prüfen

229 POSTER Combination effects of SF1126, a vascular targeted PI3 kinase inhibitor, with herceptin in Her-2 overexpressing breast cancer cells

European journal of cancer supplements, 2008, Vol.6 (12), p.72-72

2008

Link zum Volltext

Verfügbarkeit prüfen

274 Insulin-like growth factor-binding protein 3: single-agent and synergistic effects with paclitaxel in breast tumour models

European journal of cancer supplements, 2004-09, Vol.2 (8), p.84-84

2004

Link zum Volltext

Verfügbarkeit prüfen

2753 Feasibility of implementing routine genomic and proteomic profiling for advanced GYN malignancies

European journal of cancer (1990), 2015-09, Vol.51, p.S548-S548

2015

Link zum Volltext

Verfügbarkeit prüfen

28P Enriched Molecular Function Signatures in Triple Negative and Hormone Receptor Positive Breast Cancer Associated with Metastasis

Annals of oncology, 2012-05, Vol.23, p.ii22-ii23

2012

Link zum Volltext

Verfügbarkeit prüfen

2'Fluoro-5-iodo-arabinosyl-cytosine: a new agent for herpes infections in the immunosuppressed patient

Drug intelligence & clinical pharmacy, 1984-11, Vol.18 (11), p.885

1984

Link zum Volltext

Verfügbarkeit prüfen

306PD - PIK3CA alterations in metastatic breast cancer (mBC)

Annals of oncology, 2019-10, Vol.30, p.v104-v105

2019

Link zum Volltext

Verfügbarkeit prüfen

306PDPIK3CA alterations in metastatic breast cancer (mBC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

375 Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+ Breast Cancer Resistant to Trastuzumab Therapy

European journal of cancer (1990), 2012-11, Vol.48, p.114-115

2012

Link zum Volltext

Verfügbarkeit prüfen

376 Wnt-beta-catenin Pathway Controls Metastasis-associated Phenotypes of Tumor Cells in the Triple Negative Subset of Breast Cancer: a Proof of Concept Study

European journal of cancer (1990), 2012-11, Vol.48, p.115-115

2012

Link zum Volltext

Verfügbarkeit prüfen

399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study

European journal of cancer (1990), 2014-11, Vol.50, p.128-128

2014

Link zum Volltext

Verfügbarkeit prüfen

4-Ipomeanol: A Novel Investigational New Drug for Lung Cancer

JNCI : Journal of the National Cancer Institute, 1989-08, Vol.81 (15), p.1133-1143

1989

Link zum Volltext

Verfügbarkeit prüfen

42PLOW EXPRESSION OF FGD3, A PUTATIVE GUANINE NUCLEOTIDE EXCHANGE FACTOR FOR CDC42, IS PROGNOSTIC OF POOR OUTCOME IN BREAST CANCER

Annals of oncology, 2014-05, Vol.25 (suppl_1), p.i14-i14

2014

Link zum Volltext

Verfügbarkeit prüfen

5-Methyltetrahydrohomofolate

Investigational new drugs, 1987-01, Vol.5 (3), p.215-218

1987

Link zum Volltext

Verfügbarkeit prüfen

586 POSTER Inhibition of mTOR and targeting insulin-like growth factor I synergistically enhance taxol-induced cytotoxicity in Her-2 overexpressing breast cancer cells

European journal of cancer supplements, 2006-11, Vol.4 (12), p.177-177

2006

Link zum Volltext

Verfügbarkeit prüfen

60 Concurrent targeted and chemotherapy treatments is the best way to go

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S23-S23

Leyland-Jones, B.

2003

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3018: RET rearrangements as promising therapeutic targets in breast cancer

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3018-3018

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-3-11: Tivozanib in combination with paclitaxel vs placebo with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.OT2-3-11-OT2-3-11

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 301

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(267)
Mit Volltextzugriff
(258)

Publikationsform

Sprache

Englisch
(300)
Japanisch
(17)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(145)
Science & Technology
(135)
Life Sciences & Biomedicine
(133)
Oncology
(108)
Biological And Medical Sciences
(79)
Medical Sciences
(78)
Female
(67)
Pharmacology. Drug Treatments
(65)
Antineoplastic Agents
(48)
Animals
(44)
Drug Evaluation
(41)
Middle Aged
(34)
Chemotherapy
(32)
Adult
(30)
Male
(30)
Antineoplastic Agents - Therapeutic Use
(29)
Neoplasms - Drug Therapy
(29)
Pharmacology & Pharmacy
(28)
Aged
(27)
Breast Neoplasms - Drug Therapy
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

1083 A completed phase I/II trial of neoadjuvant chemotherapy (CT) with cisplatin and vinorelbine followed by accelerated thoracic irradiation, (TRT) in inoperable NSCLC

1574P - Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates

1574PSurvival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates

19P Her2 Extracellular Domain Levels in Patients With Her2-Positive Early Breast Cancer Experiencing Disease Progression: Case-Control Comparison of Samples from the Hera Study

2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug

2'-Fluoro-5-iodoarabinosylcytosine, a new potent antiviral agent: efficacy in immunosuppressed individuals with herpes zoster

2105 POSTER An accelerated loading regimen for trastuzumab leads to early higher than steady-state serum concentrations

218PAutoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial

229 POSTER Combination effects of SF1126, a vascular targeted PI3 kinase inhibitor, with herceptin in Her-2 overexpressing breast cancer cells

274 Insulin-like growth factor-binding protein 3: single-agent and synergistic effects with paclitaxel in breast tumour models

2753 Feasibility of implementing routine genomic and proteomic profiling for advanced GYN malignancies

28P Enriched Molecular Function Signatures in Triple Negative and Hormone Receptor Positive Breast Cancer Associated with Metastasis

2'Fluoro-5-iodo-arabinosyl-cytosine: a new agent for herpes infections in the immunosuppressed patient

306PD - PIK3CA alterations in metastatic breast cancer (mBC)

306PDPIK3CA alterations in metastatic breast cancer (mBC)

375 Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+ Breast Cancer Resistant to Trastuzumab Therapy

376 Wnt-beta-catenin Pathway Controls Metastasis-associated Phenotypes of Tumor Cells in the Triple Negative Subset of Breast Cancer: a Proof of Concept Study

399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study

4-Ipomeanol: A Novel Investigational New Drug for Lung Cancer

42PLOW EXPRESSION OF FGD3, A PUTATIVE GUANINE NUCLEOTIDE EXCHANGE FACTOR FOR CDC42, IS PROGNOSTIC OF POOR OUTCOME IN BREAST CANCER

5-Methyltetrahydrohomofolate

586 POSTER Inhibition of mTOR and targeting insulin-like growth factor I synergistically enhance taxol-induced cytotoxicity in Her-2 overexpressing breast cancer cells

60 Concurrent targeted and chemotherapy treatments is the best way to go

Abstract 3018: RET rearrangements as promising therapeutic targets in breast cancer

Abstract OT2-3-11: Tivozanib in combination with paclitaxel vs placebo with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer

Suchergebnisse filtern